Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 2 | EJNMMI Radiopharmacy and Chemistry

Fig. 2

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Fig. 2

Binding of [177Lu]Lu-DOTA-panitumumab F(ab´)2 to EGFR-overexpressing MDA-MB-468 human breast cancer cells in the absence (total binding; TB) or presence (non-specific binding; NSB) of an excess (2500 nmoles/L) of panitumumab IgG. Specific binding (SB) was calculated by subtracting NSB from TB. Curves were fitted to a one-site receptor binding model using Prism Ver. 4.0 software (GraphPad). Error bars represent the mean ± SD of duplicate samples. In the representative assay shown, Kd = 2.9 ± 0.7 × 10− 9 mol/L and Bmax = 1.1 ± 0.1 × 106 EGFR/cell

Back to article page